
Worcester Biotech Business Park Lands Financing for Site Preparation
A planned biomanufacturing business park on the grounds of the former Worcester State Hospital is moving forward thanks to financing from Country Bank.
A planned biomanufacturing business park on the grounds of the former Worcester State Hospital is moving forward thanks to financing from Country Bank.
One of Boston’s largest life science developers is joining hands with MIT, Harvard and five of the region’s top hospitals in a consortium to build a facility that can spark the next generation of biomedical innovation and manufacturing in Greater Boston.
Proper maintenance is key to maximizing the value of your facilities. Over-maintaining a facility provides maximum reliability, but it comes with a cost, while under-maintaining it yields cost savings but long-term reliability problems. The key is to find a sweet spot in the middle.
Many times, lab managers and facility staff are left out of the planning phase. Often, by the time they are brought in, they are faced with solving problems that could have been avoided if only their voices were heard earlier in the process.
Massachusetts’ biotech industry is rapidly growing, but a new report makes clear just how much.
A Billerica commercial building has sold to a pharmaceutical research firm for $2.55 million.
A Marlborough biopharmaceutical facility has been sold for $4.5 million on Dec. 18, according to Middlesex County land records.
Pharmaceutical company Allergan plc, makers of Botox, will establish a research facility in Cambridge’s Kendall Square.
German pharmaceutical contract development and manufacturing company Rentschler Biopharma SE has completed its purchase of a Shire manufacturing plant in Milford.
Take the pulse of the commercial real estate market right now and you’ll see a fundamental imbalance in the supply and demand for office space in the city of Boston.
This summer’s BIOInternational conference included lots of good news for the life sciences sector in Massachusetts.
More than one-third of all venture capital money invested in biopharmaceutical companies last year went to Massachusetts companies, with the bulk of those dollars headed to companies in Cambridge and nearby, according to a new industry report.